Tobramycin Sulfate (Tobramycin Sulfate) Patent Expiration, LOE Window & CMS Spending

Tobramycin Sulfate (Tobramycin Sulfate) by Fresenius Kabi: Off-Patent Genericized (AB Competition), 12 AB generics, $9.6M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN050789 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$9.6M
2024 Medicare Part D Spend$7.3M
2024 Medicaid Spend$2.2M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 142.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.